Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003)

International Journal of Antimicrobial Agents
Jennifer M StreitThomas R Fritsche

Abstract

Gastroenteritis-causing pathogens are the second leading cause of morbidity and mortality worldwide. Complicating the clinical diarrhoea syndrome is the emergence of antimicrobial resistance among the responsible bacterial pathogens. The reported increases in fluoroquinolone resistance in Salmonella, Shigella and Campylobacter have been extremely worrisome considering the primary role of ciprofloxacin as a treatment. In this study, 1479 bacterial isolates from gastroenteritis infections were collected in Europe and Latin America, which included Salmonella spp. (834; 56%), Shigella spp. (311; 21%), Campylobacter spp. (182; 12%) and Aeromonas spp. (72; 5%). The fluoroquinolones displayed the greatest activity against these pathogens, with only three non-Campylobacter spp. strains being non-susceptible using current Clinical and Laboratory Standards Institute (CLSI) breakpoint criteria. Whilst ciprofloxacin resistance in European and Latin American Salmonella was only 0.2% and 0.0%, respectively, a total of 16.2% and 12.9% of isolates were resistant to nalidixic acid, indicating possible first-step gyrA mutations. Among confirmed extended-spectrum beta-lactamase-producing Salmonella strains, CTX-M genes were detected in 15 origina...Continue Reading

Citations

Aug 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jérôme PacanowskiUNKNOWN CAMPYL Study Group
Sep 28, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Yihai GuShenghui Cui
Jul 3, 2013·International Journal of Environmental Research and Public Health·Claire VerraesLieve Herman
Feb 19, 2014·Journal of Epidemiology and Global Health·Stephen R BenoitKim Lindblade
Dec 15, 2010·Diagnostic Microbiology and Infectious Disease·Rong ZhangXin-you Xie
Mar 11, 2008·International Journal of Antimicrobial Agents·Jean-Marie SireEdgard Adam Macondo
Jul 3, 2013·Scandinavian Journal of Infectious Diseases·Virginie PrendkiNicole Desplaces
Nov 4, 2008·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Marina Macedo-ViñasRafael Vignoli
Jun 20, 2014·PLoS Neglected Tropical Diseases·Sarah Abdalla AhmedWendy W J van de Sande
Dec 3, 2010·Current Opinion in Gastroenterology·Beth D Kirkpatrick, David R Tribble
Mar 27, 2015·Journal of Clinical Microbiology·Fernando PasteranUNKNOWN ReLAVRA Network Group
Jun 13, 2009·Journal of Food Protection·J M MirandaJ A Rodriguez
Mar 25, 2021·Biomédica : revista del Instituto Nacional de Salud·Edna Catering RodríguezFrancia Patricia Correa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Campylobacteriosis

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.